Published in Virchows Arch on December 02, 2003
1,25(OH)2vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology (2011) 1.18
1,25(OH)(2)vitamin D(3) enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C(2)C(12) skeletal muscle cells. J Steroid Biochem Mol Biol (2012) 0.94
Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture. BMC Cancer (2013) 0.84
Genetic variants in the vitamin D pathway and breast cancer disease-free survival. Carcinogenesis (2012) 0.82
Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer. Acta Vet Scand (2008) 0.78
Optical tecnology developments in biomedicine: history, current and future. Transl Med UniSa (2011) 0.77
1,25-Vitamin D3 promotes cardiac differentiation through modulation of the WNT signaling pathway. J Mol Endocrinol (2014) 0.76
1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria. PLoS One (2013) 0.76
Vitamin D induces myogenic differentiation in skeletal muscle derived stem cells. Endocr Connect (2017) 0.76
The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer (1997) 5.01
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med (1998) 2.54
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev (2003) 2.22
Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol (1996) 2.21
Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett (1986) 1.68
Characterization of mouse ribosomal gene fragments purified by molecular cloning. Gene (1979) 1.64
Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer (2002) 1.48
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol (1998) 1.40
Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol (2001) 1.40
1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev (1997) 1.29
ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res (1989) 1.21
Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer (1994) 1.21
Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer (1996) 1.16
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ (2000) 1.14
Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest (1996) 1.09
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol (1997) 1.08
Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res (1991) 1.06
Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology (1988) 1.06
Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids (2001) 1.04
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol (2000) 1.04
The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res (2000) 1.03
Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res (2000) 1.02
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem (1993) 1.01
Analysis of vitamin D-receptor (VDR) and retinoid X-receptor alpha in breast cancer. Histochem J (2002) 0.95
Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer (1995) 0.94
1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis (1994) 0.92
Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol (1998) 0.92
Structure and function of the urokinase receptor. Thromb Haemost (1999) 0.90
Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thromb Haemost (2002) 0.84
Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer (1991) 0.84
Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat (1999) 0.83
1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett (1998) 0.83
Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma. J Histochem Cytochem (1998) 0.82
Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer (1998) 0.81
Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblastic cells--relationships to plasminogen activation. J Investig Dermatol Symp Proc (1996) 0.81
Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res (2002) 0.80
Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochim Biophys Acta (1994) 0.78
Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. J Steroid Biochem Mol Biol (2003) 0.77
Human breast carcinoma slice cultures retain retinoic acid sensitivity. Braz J Med Biol Res (1996) 0.75
Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol (1991) 0.75
Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol (1993) 0.75
Effects of 1,25-dihydroxyvitamin D3 on tumor cell invasion to the extracellular matrix in human fibrosarcoma HT1080 cells and its correlation with laminin. Tumour Biol (1997) 0.75
Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res (2005) 1.46
Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer (2009) 1.19
Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat (2007) 1.09
Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy. BMC Cancer (2010) 1.00
Influence of the interaction between nodal fibroblast and breast cancer cells on gene expression. Tumour Biol (2010) 0.99
Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil. PLoS One (2013) 0.99
25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol (2006) 0.98
Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer (2004) 0.93
TP53 mutations in primary breast carcinomas from white and African-Brazilian patients. Int J Oncol (2003) 0.92
Feasibility of oncoplastic techniques in the surgical management of locally advanced breast cancer. Int J Surg (2012) 0.90
Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology (2011) 0.89
Evaluation of prognostic factors in stage IIA breast tumors and their correlation with mortality risk. Clinics (Sao Paulo) (2011) 0.89
Lipid raft disruption by docosahexaenoic acid induces apoptosis in transformed human mammary luminal epithelial cells harboring HER-2 overexpression. J Nutr Biochem (2012) 0.88
Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep (2009) 0.87
Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines. PLoS One (2011) 0.87
[Molecular biology in the prostate neoplasia]. Arq Bras Endocrinol Metabol (2006) 0.86
Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs. Head Neck (2002) 0.85
Transcriptional effects of 1,25 dihydroxyvitamin D(3) physiological and supra-physiological concentrations in breast cancer organotypic culture. BMC Cancer (2013) 0.84
Differences in transcriptional effects of 1α,25 dihydroxyvitamin D3 on fibroblasts associated to breast carcinomas and from paired normal breast tissues. J Steroid Biochem Mol Biol (2012) 0.83
JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status. Int J Mol Med (2006) 0.83
Down-regulation of ANAPC13 and CLTCL1: Early Events in the Progression of Preinvasive Ductal Carcinoma of the Breast. Transl Oncol (2012) 0.82
Influence of estradiol and triiodothyronine on breast cancer cell lines proliferation and expression of estrogen and thyroid hormone receptors. Arq Bras Endocrinol Metabol (2009) 0.81
Prion protein ablation increases cellular aggregation and embolization contributing to mechanisms of metastasis. Int J Cancer (2009) 0.80
Differentially expressed genes and estrogen receptor status in breast cancer. Int J Oncol (2003) 0.80
Immunohistochemical assessment of mucosal cytokine profile in acetic acid experimental colitis. Clinics (Sao Paulo) (2005) 0.80
TGF-β1 expression in wound healing is acutely affected by experimental malnutrition and early enteral feeding. Int Wound J (2012) 0.80
Breast cancer tissue slices as a model for evaluation of response to rapamycin. Cell Tissue Res (2013) 0.79
Expression of vitamin D receptor mRNA in the hippocampal formation of rats submitted to a model of temporal lobe epilepsy induced by pilocarpine. Brain Res Bull (2008) 0.78
Molecular targets of 1,25(OH)2D3 in HC11 normal mouse mammary cell line. J Steroid Biochem Mol Biol (2003) 0.77
Tumor microenvironmental genomic alterations in juvenile nasopharyngeal angiofibroma. Head Neck (2012) 0.76
Differential expression of apoptosis related proteins and nitric oxide synthases in Epstein Barr associated gastric carcinomas. World J Gastroenterol (2006) 0.76
Short-term specialized enteral diet fails to attenuate malnutrition impairment of experimental open wound acute healing. Nutrition (2010) 0.76
Gene expression profile in response to doxorubicin-rapamycin combined treatment of HER-2-overexpressing human mammary epithelial cell lines. Mol Cancer Ther (2011) 0.76
[Cytokine participation in the acute rejection of intestinal transplantation in rats]. Arq Gastroenterol (2004) 0.75
[Thyroid hormone profile in breast cancer patients in postmenopause]. Arq Bras Endocrinol Metabol (2012) 0.75
Transcriptional profile and response to neoadjuvante chemotherapy in breast cancer. Rev Assoc Med Bras (2011) 0.75
The expression of metaloproteinases-2 and -9 is different according to the patterns of growth and invasion in squamous cell carcinoma of the penis. Virchows Arch (2006) 0.75
Is the expression of inducible (iNOS) and endothelial (eNOS) nitric oxide synthases an early event in breast carcinogenesis? Breast J (2010) 0.75